

CLAIMS AS FILED - OZ 51770

1. Use of modulators of cytokine mediated signaling pathways in combination with integrin $\alpha_v\beta_3$ receptor antagonists for the manufacture of medicaments for the treatment or prevention of diseases.
2. Use as claimed in claim 1 for the treatment or prevention of inflammatory or autoimmune disorders.
3. Use as claimed in claim 2 for the treatment or prevention of rheumatoid arthritis.
4. Use as claimed in claim 1 wherein the modulator of cytokine mediated signalling pathways is a TNF α inhibitor.
5. Pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin $\alpha_v\beta_3$ receptor antagonist.
6. Composition as claimed in claim 5 for use as a medicament.
7. Composition as claimed in claim 6 for curing inflammatory or autoimmune disorders.
8. Use of a composition as claimed in claim 4 for the manufacture of a medicament for the treatment or prevention of diseases.
9. Use as claimed in claim 8 for the treatment or prevention of inflammatory or autoimmune disorders.
10. Use as claimed in claim 9 for the treatment or prevention of rheumatoid arthritis.
11. Trade package, comprising as pharmaceutical agent a modulator of cytokine mediated signaling pathways or/and an integrin $\alpha_v\beta_3$ receptor antagonist together with an instruction for use of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or

CLAIMS AS FILED - OZ 51770

prevention of diseases.